James D Brooks

List of Publications by Year
in descending order

167 papers	7,166 citations	66343 42 h-index	64796 79 g-index
170 all docs	170 docs citations	170 times ranked	10407 citing authors

#	Article	IF	Citations
1	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 811-816.	7.1	1,175
2	Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biology, 2013, 14, R102.	9.6	291
3	GSTP1 CpG Island Hypermethylation Is Responsible for the Absence of GSTP1 Expression in Human Prostate Cancer Cells. American Journal of Pathology, 2001, 159, 1815-1826.	3.8	219
4	PLASMA SELENIUM LEVEL BEFORE DIAGNOSIS AND THE RISK OF PROSTATE CANCER DEVELOPMENT. Journal of Urology, 2001, 166, 2034-2038.	0.4	214
5	DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Research, 2011, 21, 1017-1027.	5.5	206
6	Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma. PLoS Medicine, 2005, 3, e13.	8.4	182
7	Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. European Urology Focus, 2019, 5, 592-599.	3.1	179
8	Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3334-3339.	7.1	174
9	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biology, 2002, 3, RESEARCH0032.	9.6	158
10	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Research, 2021, 81, 1583-1594.	0.9	140
11	Increased Risk of Cancer in Infertile Men: Analysis of U.S. Claims Data. Journal of Urology, 2015, 193, 1596-1601.	0.4	135
12	Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate, 1995, 26, 35-39.	2.3	123
13	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.4	122
14	Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate, 2004, 59, 243-251.	2.3	116
15	Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. International Journal of Cancer, 2014, 134, 2245-2252.	5.1	114
16	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	3.7	107
17	Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells. Journal of Biological Chemistry, 2002, 277, 14877-14883.	3.4	101
18	Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer Cells. Molecular Biology of the Cell, 2004, 15, 506-519.	2.1	100

#	Article	IF	Citations
19	Translational genomics: The challenge of developing cancer biomarkers. Genome Research, 2012, 22, 183-187.	5.5	94
20	Preoperative PSA Velocity Is an Independent Prognostic Factor for Relapse After Radical Prostatectomy. Journal of Clinical Oncology, 2005, 23, 6157-6162.	1.6	92
21	Simultaneous transrectal ultrasound and photoacoustic human prostate imaging. Science Translational Medicine, 2019, 11, .	12.4	87
22	Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma. Urology, 2014, 83, 774-780.	1.0	85
23	Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2032-2042.	7.1	85
24	Resveratrol-Induced Gene Expression Profiles in Human Prostate Cancer Cells. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 596-604.	2.5	75
25	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	5.5	71
26	Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. Urology, 2010, 75, 407-413.	1.0	70
27	MALE PELVIC ANATOMY RECONSTRUCTED FROM THE VISIBLE HUMAN DATA SET. Journal of Urology, 1998, 159, 868-872.	0.4	63
28	Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate, 2005, 63, 187-197.	2.3	62
29	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	3.1	60
30	The m ⁶ A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21441-21449.	7.1	56
31	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	2.3	55
32	NUSAP1 promotes invasion and metastasis of prostate cancer. Oncotarget, 2017, 8, 29935-29950.	1.8	55
33	Increased expression of GCNT1 is associated with altered O -glycosylation of PSA, PAP, and MUC1 in human prostate cancers. Prostate, 2014, 74, 1059-1067.	2.3	52
34	Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. Journal of Cellular Physiology, 2007, 210, 111-121.	4.1	49
35	Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. Prostate, 2009, 69, 181-190.	2.3	48
36	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canaryâ€“Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	1.9	48

#	Article	IF	Citations
37	Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer, 2017, 17, 273.	2.6	48
38	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology, 2020, 38, 1549-1557.	1.6	48
39	NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells. Prostate, 2015, 75, 517-526.	2.3	46
40	The Role of DNA Methylation in Renal Cell Carcinoma. Molecular Diagnosis and Therapy, 2018, 22, 431-442.	3.8	46
41	ProsRegNet: A deep learning framework for registration of MRI and histopathology images of the prostate. Medical Image Analysis, 2021, 68, 101919.	11.6	46
42	Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. Genome Biology, 2003, 4, R37.	9.6	45
43	GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate, 2016, 76, 199-206.	2.3	45
44	Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. Journal of Molecular Medicine, 2006, 84, 919-931.	3.9	44
45	DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Medicine, 2014, 12, 235.	5.5	42
46	LOWER BODY MASS INDEX IS ASSOCIATED WITH A HIGHER PROSTATE CANCER DETECTION RATE AND LESS FAVORABLE PATHOLOGICAL FEATURES IN A BIOPSY POPULATION. Journal of Urology, 2004, 171, 2199-2202.	0.4	41
47	S100A10 Is a Critical Mediator of GAS6/AXLâ€“Induced Angiogenesis in Renal Cell Carcinoma. Cancer Research, 2019, 79, 5758-5768.	0.9	39
48	Anatomy of the Rectourethralis Muscle. European Urology, 2002, 41, 94-100.	1.9	38
49	Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome. BMC Genomics, 2007, 8, 376.	2.8	38
50	Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. Scientific Reports, 2018, 8, 6509.	3.3	38
51	Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging. International Journal of Cancer, 2020, 147, 256-265.	5.1	38
52	Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome. Journal of Molecular Medicine, 2009, 87, 623-632.	3.9	35
53	Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. JAMIA Open, 2019, 2, 150-159.	2.0	35
54	Prostate Cancer Risk Profiles of Asian-American Men: Disentangling the Effects of Immigration Status and Race/Ethnicity. Journal of Urology, 2014, 191, 952-956.	0.4	34

#	Article	IF	Citations
55	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. European Radiology, 2016, 26, 2798-2807.	4.5	33
56	Modest induction of phase 2 enzyme activity in the F-344 rat prostate. BMC Cancer, 2006, 6, 62.	2.6	32
57	Molecular genetics and chromosomal alterations in prostate cancer. Cancer, 1995, 75, 2004-2012.	4.1	31
58	Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer. EGEMS (Washington, DC), 2018, 6, 13.	2.0	31
59	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	1.9	30
60	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	7.1	30
61	Anatomy of the Lower Urinary Tract and Male Genitalia. , 2012, , 33-70.e2.		30
62	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2020, 203, 727-733.	0.4	30
63	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	2.5	28
64	Registration of presurgical MRI and histopathology images from radical prostatectomy via RAPSODI. Medical Physics, 2020, 47, 4177-4188.	3.0	28
65	Automated detection of aggressive and indolent prostate cancer on magnetic resonance imaging. Medical Physics, 2021, 48, 2960-2972.	3.0	27
66	3D Registration of pre-surgical prostate MRI and histopathology images via super-resolution volume reconstruction. Medical Image Analysis, 2021, 69, 101957.	11.6	26
67	Genomic analysis of benign prostatic hyperplasia implicates cellular relandscaping in disease pathogenesis. JCI Insight, 2019, 4, .	5.0	26
68	Microarray analysis in prostate cancer research. Current Opinion in Urology, 2002, 12, 395-399.	1.8	25
69	hCAP-D3 Expression Marks a Prostate Cancer Subtype With Favorable Clinical Behavior and Androgen Signaling Signature. American Journal of Surgical Pathology, 2008, 32, 205-209.	3.7	25
70	Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?. Urology, 2017, 100, 65-71.	1.0	25
71	Selective identification and localization of indolent and aggressive prostate cancers via CorrSigNIA: an MRI-pathology correlation and deep learning framework. Medical Image Analysis, 2022, 75, 102288.	11.6	25
72	A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers. Advances in Anatomic Pathology, 2013, 20, 39-44.	4.3	24

#	Article	IF	Citations
73	Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?. European Urology, 2016, 70, 227-230.	1.9	24
74	Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics and Proteomics, 2005, 2, 97-114.	2.0	23
75	Selenomethionine Induced Transcriptional Programs in Human Prostate Cancer Cells. Journal of Urology, 2007, 177, 743-750.	0.4	22
76	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	3.9	22
77	Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. Oncotarget, 2017, 8, 18657-18669.	1.8	21
78	MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Scientific Reports, 2021, 11, 13305.	3.3	20
79	Oncogene-mediated metabolic gene signature predicts breast cancer outcome. Npj Breast Cancer, 2021, 7, 141.	5.2	20
80	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	2.3	19
81	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	2.5	19
82	Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice. Journal of Urology, 2012, 188, 1033-1041.	0.4	18
83	Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies. PLoS ONE, 2019, 14, e0221051.	2.5	18
84	Leveraging Digital Data to Inform and Improve Quality Cancer Care. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 816-822.	2.5	18
85	SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports Medicine, 2022, 3, 100502.	6.5	18
86	PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 795-803.	4.9	17
87	Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology. Journal of Magnetic Resonance Imaging, 2012, 36, 206-212.	3.4	16
88	Managing localized prostate cancer in the era of prostateâ€specific antigen screening. Cancer, 2013, 119, 3906-3909.	4.1	16
89	Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction. Journal of Pediatric Urology, 2019, 15, 44.e1-44.e7.	1.1	16
90	Association between patientâ€initiated emails and overall 2â€year survival in cancer patients undergoing chemotherapy: Evidence from the realâ€world setting. Cancer Medicine, 2020, 9, 8552-8561.	2.8	16

#	Article	IF	Citations
91	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget, 2018, 9, 6550-6561.	1.8	16
92	Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. Human Pathology, 2001, 32, 441-446.	2.0	15
93	Alteration of Gene Expression Signatures of Cortical Differentiation and Wound Response in Lethal Clear Cell Renal Cell Carcinomas. PLoS ONE, 2009, 4, e6039.	2.5	15
94	The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-13C]-ketoisocaproate. Magnetic Resonance Imaging, 2014, 32, 791-795.	1.8	15
95	A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers. PLoS ONE, 2015, 10, e0139484.	2.5	15
96	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer, 2019, 125, 943-951.	4.1	15
97	Clinical Trial Outcomes in Urology: Assessing Early Discontinuation, Results Reporting and Publication in ClinicalTrials.Gov Registrations 2007â€“2019. Journal of Urology, 2021, 205, 1159-1168.	0.4	15
98	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2017, 197, 1026-1033.	0.4	13
99	Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions. JCO Clinical Cancer Informatics, 2021, 5, 1106-1126.	2.1	13
100	Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry. Scientific Reports, 2019, 9, 11007.	3.3	12
101	Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients. Journal of Biomedical Informatics, 2019, 94, 103184.	4.3	12
102	The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. Journal of Urology, 2018, 200, 541-548.	0.4	11
103	Phenotyping severity of patientâ€centered outcomes using clinical notes: A prostate cancer use case. Learning Health Systems, 2020, 4, e10237.	2.0	11
104	Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance. European Urology Open Science, 2021, 23, 20-29.	0.4	11
105	Development of a DNA Methylationâ€“Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. JCO Precision Oncology, 2020, 4, 1141-1151.	3.0	10
106	Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment. AMIA ... Annual Symposium proceedings, 2017, 2017, 876-882.	0.2	10
107	Protein signatures to distinguish aggressive from indolent prostate cancer. Prostate, 2022, 82, 605-616.	2.3	10
108	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for â€œlargeâ€•cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	5.5	10

#	Article	IF	Citations
109	Bridging the gap between prostate radiology and pathology through machine learning. Medical Physics, 2022, 49, 5160-5181.	3.0	10
110	Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. American Journal of Physiology - Renal Physiology, 2018, 315, F16-F26.	2.7	9
111	miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2019, 3, 119-132.	0.4	9
112	Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 734.e1-734.e10.	1.6	9
113	The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy. Journal of Urology, 2020, 204, 231-238.	0.4	9
114	Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. Journal of Clinical Oncology, 2016, 34, 3586-3587.	1.6	8
115	Early-Life Cardiorespiratory Fitness and Long-term Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2187-2194.	2.5	8
116	In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification. Cancer Research, 2021, 81, 2510-2521.	0.9	8
117	Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy. EGEMS (Washington, DC), 2019, 7, 43.	2.0	8
118	Silencing of ?-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate, 2002, 51, 225-230.	2.3	7
119	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. European Urology Focus, 2018, 4, 360-368.	3.1	7
120	Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 217-226.	0.7	7
121	Weakly Supervised Registration ofÂProstate MRI and Histopathology Images. Lecture Notes in Computer Science, 2021, , 98-107.	1.3	7
122	Assessment of a Clinical Trialâ€“Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2021, 4, e2031730.	5.9	7
123	The Impact of Tumor Volume on Outcomes after Radical Prostatectomy: Implications for Prostate Cancer Screening. The Open Prostate Cancer Journal, 2008, 1, 1-8.	0.4	7
124	Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer. Studies in Health Technology and Informatics, 2019, 264, 1522-1523.	0.3	7
125	Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance. PLoS ONE, 2017, 12, e0186026.	2.5	6
126	Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study. BMJ Open, 2019, 9, e027182.	1.9	6

#	Article	IF	Citations
127	Sprr2f protects against renal injury by decreasing the level of reactive oxygen species in female mice. American Journal of Physiology - Renal Physiology, 2020, 319, F876-F884.	2.7	6
128	Laboratoryâ€wide association study of survival with prostate cancer. Cancer, 2021, 127, 1102-1113.	4.1	6
129	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology, 2021, 155, 70-76.	1.0	6
130	Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 868-75.	2.5	6
131	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Human Pathology, 2022, 122, 84-91.	2.0	6
132	Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer. Carbohydrate Research, 2022, 519, 108598.	2.3	6
133	Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy. Research and Reports in Urology, 2018, Volume 10, 233-235.	1.0	5
134	Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. Journal of Clinical Pathology, 2019, 72, 696-704.	2.0	5
135	Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer . Research and Reports in Urology, 2020, Volume 12, 7-14.	1.0	5
136	Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patientâ€reported outcomes. Cancer Medicine, 2021, 10, 5783-5793.	2.8	5
137	A natural language processing algorithm to measure quality prostate cancer care.. Journal of Clinical Oncology, 2017, 35, 232-232.	1.6	5
138	Identifying Cases of Metastatic Prostate Cancer Using Machine Learning on Electronic Health Records. AMIA ... Annual Symposium proceedings, 2018, 2018, 1498-1504.	0.2	5
139	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. Clinical Genitourinary Cancer, 2018, 16, e181-e192.	1.9	4
140	Applying the PRECISION approach in biopsy naÃ¯ve and previously negative prostate biopsy patients. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 530.e19-530.e24.	1.6	4
141	Prevalence of Postprostatectomy Incontinence Requiring Anti-incontinence Surgery After Radical Prostatectomy for Prostate Cancer: A Retrospective Population-Based Analysis. International Neurourology Journal, 2021, 25, 263-270.	1.2	4
142	Framework for the co-registration of MRI and histology images in prostate cancer patients with radical prostatectomy. , 2019, , .		4
143	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	4.1	3
144	Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e23-12.e30.	1.6	3

#	Article	IF	Citations
145	Detection of prostate cancer and determination of its significance using explainable artificial intelligence.. Journal of Clinical Oncology, 2020, 38, 5555-5555.	1.6	3
146	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.4	3
147	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	2.8	3
148	Application of Genomic Technologies to Human Prostate Cancer. OMICS A Journal of Integrative Biology, 2006, 10, 261-275.	2.0	2
149	Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 360-364.	5.4	2
150	An Automated Feature Engineering for Digital Rectal Examination Documentation using Natural Language Processing. AMIA ... Annual Symposium proceedings, 2018, 2018, 288-294.	0.2	2
151	Consumption of cruciferous vegetables and the risk of bladder cancer in a prospective US cohort: data from the NIH-AARP diet and health study. American Journal of Clinical and Experimental Urology, 2021, 9, 229-238.	0.4	2
152	Epigenetic Changes in Histologically Normal Prostate Tissues. Journal of Urology, 2013, 189, 2020-2021.	0.4	1
153	Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Lowâ€“Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146â€“54. European Urology, 2018, 74, e110-e111.	1.9	1
154	AZGP1 Protein Expression in Hormone-NaÃ¯ve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. Diagnostics, 2020, 10, 520.	2.6	1
155	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. Urology Practice, 2021, 8, 576-582.	0.5	1
156	Determination of biologic and prognostic feature scores from whole slide histology images using deep learning.. Journal of Clinical Oncology, 2020, 38, e17527-e17527.	1.6	1
157	Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer. Journal of Urology, 2022, 208, 80-89.	0.4	1
158	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.4	1
159	Reply. Urology, 2014, 83, 779-780.	1.0	0
160	Sudden PSA rise to â‰¥20 ng/ml and prostate cancer diagnosis in the United States: A populationâ€based study. Prostate, 2020, 80, 1438-1443.	2.3	0
161	Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data.. Journal of Clinical Oncology, 2021, 39, 1511-1511.	1.6	0
162	AUTHOR REPLY. Urology, 2021, 155, 76.	1.0	0

#	Article	IF	Citations
163	Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis.. Journal of Clinical Oncology, 2017, 35, 171-171.	1.6	0
164	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).. Journal of Clinical Oncology, 2017, 35, 22-22.	1.6	0
165	Editorial Comment. Journal of Urology, 2020, 203, 350-350.	0.4	0
166	PIVOT and the challenges of localized prostate cancer care. Translational Andrology and Urology, 2012, 1, 141-3.	1.4	0
167	Editorial Comment on Considerations in the Analysis of Clinical Trial Failure. I. Journal of Urology, 2022, , 101097JU0000000000002428.	0.4	0